Clinical trial
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
NCT07644832 is registered in ClinicalTrials.gov with Shanghai RAAS Blood Products Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Lead sponsor
- Shanghai RAAS Blood Products Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- May 31, 2024
- Completion date
- December 31, 2026
- Enrollment
- 76 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.